CR10450A - Metodo para inhibir la cinasa del c-kit - Google Patents

Metodo para inhibir la cinasa del c-kit

Info

Publication number
CR10450A
CR10450A CR10450A CR10450A CR10450A CR 10450 A CR10450 A CR 10450A CR 10450 A CR10450 A CR 10450A CR 10450 A CR10450 A CR 10450A CR 10450 A CR10450 A CR 10450A
Authority
CR
Costa Rica
Prior art keywords
kit
inhibiting
subject
present
cell proliferative
Prior art date
Application number
CR10450A
Other languages
English (en)
Spanish (es)
Inventor
R Illig Carl
K Ballentine Shelley
Chen Jinsheng
K Meegalla Sanath
Jonathan Rudolph M
J Wall Mark
L Desjarlais Renee
Wilson Kenneth
L Manthey Carl
Flores Christopher
j molloy Christopher
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR10450A publication Critical patent/CR10450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR10450A 2006-04-20 2008-11-20 Metodo para inhibir la cinasa del c-kit CR10450A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79347106P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
CR10450A true CR10450A (es) 2009-02-23

Family

ID=38625740

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10450A CR10450A (es) 2006-04-20 2008-11-20 Metodo para inhibir la cinasa del c-kit

Country Status (21)

Country Link
EP (2) EP2015748B1 (cg-RX-API-DMAC7.html)
JP (1) JP5595727B2 (cg-RX-API-DMAC7.html)
KR (1) KR101448052B1 (cg-RX-API-DMAC7.html)
CN (2) CN101610768B (cg-RX-API-DMAC7.html)
AU (1) AU2007240400B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710542B8 (cg-RX-API-DMAC7.html)
CA (1) CA2649755C (cg-RX-API-DMAC7.html)
CO (1) CO6382175A2 (cg-RX-API-DMAC7.html)
CR (1) CR10450A (cg-RX-API-DMAC7.html)
EA (1) EA016611B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP088842A (cg-RX-API-DMAC7.html)
ES (2) ES2458291T3 (cg-RX-API-DMAC7.html)
GT (1) GT200800225A (cg-RX-API-DMAC7.html)
IL (1) IL194846A (cg-RX-API-DMAC7.html)
MX (1) MX2008013528A (cg-RX-API-DMAC7.html)
MY (1) MY147226A (cg-RX-API-DMAC7.html)
NO (1) NO342001B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ572200A (cg-RX-API-DMAC7.html)
SG (1) SG171592A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007124369A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200809874B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101924247B1 (ko) 2011-07-27 2019-02-22 에이비 사이언스 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
US10259807B2 (en) 2013-07-22 2019-04-16 Idorsia Pharmaceuticals Ltd. 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
CA2972952C (en) 2015-01-15 2021-01-05 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332948T2 (de) 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
ATE375342T1 (de) * 2002-08-02 2007-10-15 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
ATE465731T1 (de) * 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
AU2005209485A1 (en) * 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
MX2007004784A (es) * 2004-10-22 2007-09-11 Johnson & Johnson Inhibidores de la c-fms cinasa.
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
JP2009511628A (ja) * 2005-10-18 2009-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｌｔ３キナーゼの阻害方法
CA2649736C (en) * 2006-04-20 2013-11-26 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
CN101466686A (zh) * 2006-04-20 2009-06-24 詹森药业有限公司 C-fms激酶抑制剂
CA2649924C (en) * 2006-04-20 2014-08-19 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase

Also Published As

Publication number Publication date
EP2015748B1 (en) 2012-07-04
CO6382175A2 (es) 2012-02-15
BRPI0710542A2 (pt) 2012-06-05
WO2007124369A2 (en) 2007-11-01
BRPI0710542B8 (pt) 2021-05-25
ES2389678T3 (es) 2012-10-30
NO342001B1 (no) 2018-03-12
EP2397138B1 (en) 2013-12-11
KR20080111545A (ko) 2008-12-23
IL194846A0 (en) 2009-08-03
AU2007240400B2 (en) 2013-08-22
HK1124766A1 (en) 2009-07-24
AU2007240400A1 (en) 2007-11-01
WO2007124369A3 (en) 2008-03-06
CN102670605A (zh) 2012-09-19
EP2015748A2 (en) 2009-01-21
EP2397138A1 (en) 2011-12-21
GT200800225A (es) 2009-05-15
EA200870454A1 (ru) 2009-04-28
BRPI0710542B1 (pt) 2021-01-12
NO20084892L (no) 2009-01-06
KR101448052B1 (ko) 2014-10-07
MY147226A (en) 2012-11-14
SG171592A1 (en) 2011-06-29
JP2009534418A (ja) 2009-09-24
CA2649755A1 (en) 2007-11-01
CN101610768B (zh) 2012-03-21
NZ572200A (en) 2011-09-30
IL194846A (en) 2015-07-30
CN102670605B (zh) 2015-07-29
JP5595727B2 (ja) 2014-09-24
CA2649755C (en) 2014-12-02
ES2458291T3 (es) 2014-04-30
ZA200809874B (en) 2010-02-24
EA016611B1 (ru) 2012-06-29
CN101610768A (zh) 2009-12-23
ECSP088842A (es) 2008-11-27
MX2008013528A (es) 2008-10-29

Similar Documents

Publication Publication Date Title
CR10450A (es) Metodo para inhibir la cinasa del c-kit
ECSP088387A (es) Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms
MX2009009786A (es) Inhibidores de la via de hedgehog.
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
UA106054C2 (uk) ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИМІДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ TРK-КІНАЗИ
MX2009010929A (es) Terapias de combinacion que comprenden inhibidores de quinoxalina de pi3k-alfa para uso en el tratamiento del cancer.
WO2010068483A3 (en) Mlk inhibitors and methods of use
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
WO2011149950A3 (en) Bicyclic heteroaryl kinase inhibitors and methods of use
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
TW200614990A (en) Methods for preparing indazole compounds
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
MX2009005231A (es) Composiciones utiles como inhibidores de proteina cinasa.
MX2011012522A (es) Inhibidores de pirazol sustituido de proteina cinasa c-met.
PT2435443E (pt) Inibidores à base de aminopirazole triazolotiadiazole da proteína quinase c met
EA201270347A1 (ru) Производные апогоссиполона в качестве противоопухолевых агентов
AR065077A1 (es) Composiciones farmaceuticas y metodos para utilizar temozolomida e inhibidores de quinasa multidirigidos
WO2007050401A3 (en) Tyrosine kinase inhibitors
UA99612C2 (en) Inhibitors of the hedgehog pathway